Glucoryl M 3mg/500mg Tablet is a combination oral hypoglycemic agent containing Glimepiride 3mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. The synergistic action of these two agents addresses multiple pathophysiological defects in type 2 diabetes, making Glucoryl M effective in achieving and maintaining target blood glucose levels. This combination is typically prescribed when diet, exercise, and monotherapy with either agent do not provide adequate glycemic control. Glucoryl M should be used under medical supervision with regular monitoring of blood glucose, renal function, and potential side effects such as hypoglycemia, gastrointestinal disturbances, and lactic acidosis. Dose adjustments may be necessary based on therapeutic response and patient tolerance. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and known hypersensitivity to its components. Patient adherence to lifestyle modifications alongside pharmacotherapy is essential for optimal diabetes management with Glucoryl M.